Although the effect of erlotinib, another first-generation EGFR-TKI, on tumor growth in vivo in combination with the GLUT1 inhibitor is yet to be tested, our in vitro results suggest erlotinib would be effective similarly to gefitinib. This evidence concerns the gene EGFR and neoplasm.